Workflow of the study
MAY, DISEASE PROGRESSION
Between August 2020 and May 2022, 30 patients were enrolled, which constituted the intention-to-treat population. Until the data cutoff (May 08, 2022; end of the follow-up period), the median follow-up duration was 12.3 months (95% CI: 9.1–16.0), and the median treatment cycle for sintilimab plus chemotherapy was 5.5 (range: 1–8). Fifteen (50%) patients received 6–8 cycles of combined therapy, whereas the remaining 15 patients received less than 6 cycles of treatment. The median treatment duration was 4.3 months (range: 0.7–7.1) for chemotherapy and 4.9 months (range: 0.7–20.1) for sintilimab. Eighteen patients experienced disease progression during the combination period, while nine completed 6–8 cycles of treatment in the combination regimens and used sintilimab alone as maintenance therapy; during this period, six patients experienced disease progression and three were still undergoing sintilimab treatment. In total, 5 (17%) patients continued the study treatment without disease progression (Fig. 